Abstract
This study aims to explore the advantages and limitations of AngioJet mechanical thrombectomy combined with catheter-directed thrombolysis (CDT), providing reference for clinical treatment. Electronic medical records of 192 patients with lower extremity deep vein thrombosis (LEDVT) who visited our hospital from January 2022 to December 2023 were included. Patients were matched using propensity scores based on their thrombosis treatment method: the experimental group received AngioJet thrombectomy combined with CDT, while the control group received CDT alone. Outcomes were compared post-matching, including treatment effectiveness, coagulation, valve condition, complications, and quality of life. This study evaluated the efficacy of AngioJet mechanical thrombectomy (PMT) combined with CDT in treating acute LEDVT. The combined approach led to better vessel patency, greater limb swelling reduction, improved coagulation function, and less venous valve damage compared to CDT alone. Additionally, it significantly reduced the occurrence and severity of post-thrombotic syndrome and enhanced patient quality of life, particularly in physical pain and physiological function. The combination of PMT and CDT demonstrated superior efficacy in restoring venous function, alleviating symptoms, and reducing long-term complications. These findings support the clinical advantage of combined therapy in improving patient outcomes while maintaining a favorable safety profile.